- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 2446816-88-0] Inaxaplin
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-132820 |
| Brand: | MCE |
| CAS: | 2446816-88-0 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 417.38 |
| Molecular Formula | C21H18F3N3O3 |
| SMILES | O[C@H](CNC1=O)[C@@H]1NC(CCC(C2=CC(F)=C3)=C(C4=CC=C(C=C4)F)NC2=C3F)=O |
Summary
Inaxaplin (VX-147) is an orally active apolipoprotein L1 ( APOL1 ) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease [1] .
IC50 & Target
APOL1 [1]
In Vitro
Inaxaplin is an apolipoprotein L1 function inhibitor [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04340362 | Vertex Pharmaceuticals Incorporated |
Glomerulosclerosis, Focal Segmental
|
June 8, 2020 | Phase 2 |
| NCT05312879 | Vertex Pharmaceuticals Incorporated |
Proteinuric Kidney Disease
|
March 30, 2022 | Phase 2|Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 119.79 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3959 mL | 11.9795 mL | 23.9590 mL |
| 5 mM | 0.4792 mL | 2.3959 mL | 4.7918 mL |
| 10 mM | 0.2396 mL | 1.1979 mL | 2.3959 mL |
References
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.